3-3-2018

Hot issues in anti-platelet therapy 2018: what’s the data to guide drug selection, duration, and combinations?

Anthony DeFranco
Aurora Health Care, anthony.defranco@aurora.org

Follow this and additional works at: https://digitalrepository.aurorahealthcare.org/cardiologyfaculty

Recommended Citation
DeFranco A. Hot issues in anti-platelet therapy 2018: what’s the data to guide drug selection, duration, and combinations? Presentation at New Developments in Cardiology; March 3, 2018; Milwaukee, WI.

This Oral/Podium Presentation is brought to you for free and open access by the Aurora UW Faculty at Aurora Health Care Digital Repository. It has been accepted for inclusion in Aurora UW Cardiology Faculty by an authorized administrator of Aurora Health Care Digital Repository. For more information, please contact ewindchy@bepress.com.
General Information

New Developments in Cardiology | Saturday, March 3, 2018

Location
Milwaukee Marriott Downtown
323 E. Wisconsin Avenue | Milwaukee WI 53202

Conference Fees* (Check appropriate category)

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician/DO/PhD/PharmD/Industry</td>
<td>$130.00</td>
</tr>
<tr>
<td>Aurora Physician/DO/PhD/PharmD</td>
<td>$85.00</td>
</tr>
<tr>
<td>Allied Staff/NP/RN/MA</td>
<td>$30.00</td>
</tr>
<tr>
<td>Student/Retired Discounted fee</td>
<td>$25.00</td>
</tr>
</tbody>
</table>

*Conference fees cover tuition, materials, breaks and lunch as well as a $25.00 non-refundable registration fee. Participants may cancel up to 72 hours in advance of the symposium to receive a refund (less the $25). No refunds will be made after that time.

Conference Attire
To ensure your comfort in the conference room, please bring a sweater or jacket to accommodate temperature variations.

Information about the course
Contact Laurel Landis at 414-219-7684 or email laurel.landis@aurora.org with course related questions.

Refunds
Course fees include a $25 nonrefundable registration fee. Should you cancel up to 72 hours prior to the symposium, all but the $25 registration fee will be refunded. Refunds will not be given after that time.

Purpose
This course is designed to present new developments in the field of cardiovascular disorders, as well as their clinical applications, in order to encourage discussion and promote improved patient outcomes in all our practices.

We have chosen topics and presenters to cover the latest in familiar topics as well as map out areas of frontier exploration.

Objectives
At the end of this course, participants will be able to:
1. List the latest treatments in 5 most common vascular problems
2. Interpret the indications for action in treating
3. Compare new treatments in Cardiovascular disease

Target Audience
This symposium is designed for family practitioners, internists, cardiologists and emergency department physicians who diagnose, treat and manage patients with cardiovascular disorders. It will be of interest to fellows, residents, PA, MDs and other allied health professionals interested in cardiovascular disease.

Elements of Competence
This CME activity has been designed to change medical knowledge and patient care, two of the six competencies embraced by the American Board of Medical Specialties.

CREDIT Accreditation
Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians.

Aurora Health Care designates this live educational activity for a maximum of 6.75 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For a complete listing of Aurora Health Care CME programs visit our website at Aurora.org/CMEactivities.

Aurora Health Care subscribes to the articles of Title III of the Americans with Disabilities Act of 1990. Should you or anyone accompanying you require special assistance, please notify us at 414-219-7684.

Disclosure of Conflicts of Interest
It is the policy of the Aurora Health Care Office of Continuing Education to ensure balance, independence, objectivity and scientific rigor in all of its sponsored education activities. All participating faculty, course directors and planning committee members are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information along with the presentations are peer reviewed in advance in order to manage and resolve any possible conflicts of interest. All faculty and planning committee members have attested that their financial relationships do not affect their ability to present well-balanced, evidence-based content for this activity. Specific disclosure information for each course faculty will be shared with the audience prior to the faculty’s presentation.

Commercial funding pending and will be announced at the time of the course.

27th Annual
New Developments in Cardiology
A Comprehensive Review of Cardiology
and Vascular Medicine Issues

Saturday, March 3, 2018
Milwaukee Marriott Downtown
Milwaukee, Wisconsin
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td>8:05 a.m.</td>
<td>Surgical Treatment of End Stage Heart Failure: Mechanical Circulatory Support and Cardiac Transplantation Frank Downey, MD</td>
</tr>
<tr>
<td>8:35 a.m.</td>
<td>Atrial Fibrillation: Treatment Options in 2018                                               Jasbir Sra, MD</td>
</tr>
<tr>
<td>9:05 a.m.</td>
<td>Mitral Valve Regurgitation and Update on TAVR: Epidemiology, Presentation, Diagnosis, Evolution of Treatment Frank Dufranco, MD</td>
</tr>
<tr>
<td>9:35 a.m.</td>
<td>PFO Closure – the Glaring Evidence for a Cryptogenic Problem                                Tanvir Bajwa, MD</td>
</tr>
<tr>
<td>10:05 a.m.</td>
<td>Break and Exhibits</td>
</tr>
<tr>
<td>10:20 a.m.</td>
<td>Heart Failure with Preserved Ventricular Function: Hypertension, Clinical Presentation, Diagnosis, Treatment Nasir Z. Sulemanjee, MD, FACC, FHFSA</td>
</tr>
<tr>
<td>10:50 a.m.</td>
<td>Dyslipidemia – Update on the Treatment Option in Different Patient Populations: Statin Myths and Contraversies, Roles of PCSK9 Inhibitors in Contemporary Practice Suhail Allaqaband, MD</td>
</tr>
<tr>
<td>11:20 a.m.</td>
<td>Smoking Cessation: An Evidence-Based 2018 Update                                            Michael Fiore, MD</td>
</tr>
</tbody>
</table>